These strategies include administration of the small molecule CETP inhibitors, dalcetrapib22 and torcetrapib,23 a CETP antisense oligonucleotide,24 and an anti-CETP vaccine.25 However, the dalcetrapib data were later challenged by the group of Mabuchi in another cholesterol-fed rabbit model, which supports the contention that weak CETP inhibitors that only raise HDL-C have no effect on atherosclerosis. This evidence concerns the gene CETP and atherosclerosis.